Hepion Pharmaceuticals Inc (HEPA)

[Fress]

Hepa will go huge soon!


Primed to run!


Adding this morning thank you for the opportunity to add to my stash.


Small Biotech with unlimited upside.


HRPA CRV431 molecule in action

New Therapeutic Target in Alzheimer's Diseases; Cyclophilin A | bioscientifiq.com

"Nearly 45% of all deaths in the developed world are attributed to some type of chronic fibroproliferative disease. Therefore the demand for antifibrotic drugs that are both SAFE & EFFECTIVE is likely to be enormous."
-NIH

NASH 35 Billion dollar market today nearing 100 Billion in the next 7 years. NO approved NASH drugs to date.

In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.


HEPA With a NASH & the dozen other possible applications HEPA is looking at this can be trading 100x from currents levels.

Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/

Hobbs didn't leave 190 Billion dollar company as one of their highest level execs to become CMO for tiny HEPA unless its for a big reason.


HEPA 2 upgrades to $4.50 and $14.00

HEPA June 2021 HEPA Biz Presentation.
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf



Nash Companies in Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash.
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash.
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash.



Reeling in the blue fin tunas NVAX PDSB & HEPA is next!
https://giphy.com/gifs/natgeochannel-wicked-tuna-5qFZPAGmGiPFARl9qC


$HEPA